L-asparaginase (L-ASP)-related toxicities with Erwinia L-ASP in a large compassionate-use protocol.

Plourde, Paul V.; Jeha, Sima; Silverman, Lauren; Nachman, James B.; Rheingold, Susan R.; Dahl, Gary V.; Raetz, Elizabeth A.; Mercedes, Taheri; Corn, Tim

doi:10.1200/jco.2011.29.15_suppl.9534

Cited by 1 publication

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Asparaginase Erwinia Chrysanthemi (Erwinaze™) is an L-ASP derived from a different bacterium and is immunologically distinct from the E. coli L-ASP. Plourde et al conducted a compassionate use trial of Erwinaze in 1368 ALL patients with hypersensitivity to native E. coli or PEG-ASP to collect safety information [55]. 77.6% of patients were able to complete their Erwinaze treatment.…”

Section: Introductionmentioning

confidence: 99%

Novel agents and biomarkers for acute lymphoid leukemia

2013

View full text Add to dashboard Cite

New genetic markers for adult acute lymphoblastic leukemia (ALL) have been found to have prognostic impact, such as the lymphoid transcription factor gene IKZF1 alterations, which are associated with a high rate of leukemic relapse in B-ALL. Although complete remission rates by induction chemotherapy in ALL are now high, the long-term survival is still disappointing. Improvements in the survival outcome of ALL have been observed in young adults as a result of the use of pediatric inspired regimens and the broadening of the number of patients who are eligible for allogeneic SCT. Development of new and less toxic agents also provide promise to improve the outcome in adult ALL, such as tyrosine kinase inhibitors in Ph-positive ALL, rituximab in CD20-positive disease, blinatumomab in precursor B-ALL and nelarabine in T-lineage ALL. Challenges for the future are to implement genomic profiling into the clinical setting to guide risk stratification and providing novel targets for tailored therapies.

show abstract

Section: Introductionmentioning

confidence: 99%